From Retirement To The Front Lines Of Hepatitis C Treatment
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
Drug Costs
561-580 of 704 results
-
-
Readers Have Bones To Pick, From Health System Flaws To Covering Pot Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
FDA Chief Says He鈥檚 Open To Rethinking Incentives On Orphan Drugs
The FDA鈥檚 Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
-
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
-
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry鈥 biggest trade group raised millions to change the conversation about drug pricing.
By Jay Hancock -
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation鈥檚 most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
-
Cities, Counties and Schools Sidestep FDA Canadian Drug Crackdown, Saving Millions
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
-
Pace Of U.S. Health Spending Slows In 2016
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
-
Podcast: ‘What The Health?’ Taxes, Medicare And The Year-End Mess
In this episode of 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the possible impact of the tax bill on the Medicare program, confirmation hearings for a new secretary of Health and Human Services and the future of the Children鈥檚 Health Insurance Program. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
-
The Ratcheting Price Of The Pneumococcal Vaccine: What Gives?
The price for Pfizer鈥檚 Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
-
Heated And Deep-Pocketed Battle Erupts Over 340B Drug Discount Program
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
-
Podcast: ‘What The Health?’ Meanwhile, In Other Health News鈥
In this episode of 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Alice Ollstein of Talking Points Memo and Sarah Jane Tribble of Kaiser Health News discuss some of the under-covered health stories of the past several weeks, including drug price issues, the opioid epidemic and women鈥檚 reproductive health.
-
Massachusetts Grabs Spotlight By Proposing New Twist On Medicaid Drug Coverage
In an effort to reduce drug costs and increase efficiency, Massachusetts is seeking federal approval to implement a new approach to how the state鈥檚 Medicaid program covers prescription medications.
-
Medicare Seeks Comment On Ways To Cut Costs Of Part D Drugs
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
-
Pressure Builds To Cut Medicare Patients In On Prescription Deals
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
-
Study Gives Mixed Reviews On Laws To Equalize Cancer Patients鈥 Out-Of-Pocket Costs
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor鈥檚 office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
-
Ohio鈥檚 Drug-Pricing Ballot Question Triggers Voter Confusion
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
-
Health Companies Race To Catch UnitedHealth As Amazon Laces Up
UnitedHealth, a health industry goliath, has its hand in doctors鈥 offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are 鈥榳annabes.鈥
By Chad Terhune -
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.